You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Banner image with blue and red molecule

Congresses

Congress Materials

Access abstracts, posters, and presentations presented at the following congresses

June 2022

Asian Oncology Society (AOS)

June 2022

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2022 (Vienna, Austria)

Posters

A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress) A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study

Abstracts

A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress) A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML) Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
June 2022

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

June 2022 (Chicago, Illinois, United States)

Abstracts

A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM) ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL) Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL) Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
May 2022

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

May 2022

International Conference on Clinical and Experimental Hematology (ICCEH)

April 2022

Transplantation & Cellular Therapy (TCT)

April 2022

American Society of Clinical Oncology Plenary Series Program (ASCO)

April 2022

American Association for Cancer Research (AACR)

American Association for Cancer Research (AACR)

April 2022 (New Orleans, Louisiana, United States)
April 2022

British Society for Haematology (BSH)

March 2022

Italian Society of Experimental Hematology (SIES)

March 2022

Korean Society of Hematology (KSH)

March 2022

European Lung Cancer Congress (ELCC)

March 2022

French Society of Hematology (SFH)

March 2022

Society of Gynecologic Oncology (SGO)

March 2022

Francophone Days of Hepato-gastroenterology and Digestive Oncology (JFHOD)

March 2022

European Society of Medical Oncology Targeted Anticancer Therapies (ESMO TAT)

February 2022

Japanese Society of Medical Oncology (JSMO)

January 2022

British Thoracic Oncology Group (BTOG)

January 2022

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

January 2022 (San Francisco, CA, United States)

Posters

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208 Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors

Abstracts

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
December 2021

American Society of Hematology (ASH)

American Society of Hematology (ASH)

December 2021 (Atlanta, Georgia, United States)

Presentations

Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma Zanubrutinib in combination with venetoclax for patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial

Abstracts

Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed/refractory B-cell malignancies Preliminary safety and efficacy data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
December 2021

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

December 2021 (Geneva, Switzerland)
December 2021

Immunotherapy Bridge (IBC)

November 2021

International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)

November 2021

Australasian Melanoma Conference (AMC)

November 2021

Clinical Oncology Society of Australia (COSA)

November 2021

Portuguese Society of Hematology (SPH)

November 2021

Society for Immunotherapy of Cancer (SITC)

October 2021

Italian Society of Hematology (SIE)

October 2021

Academy of Managed Care Pharmacy Nexus (AMCP Nexus)

October 2021

Spanish Society of Medical Oncology (SEOM)

October 2021

Spanish Society of Hematology and Hemotherapy (SEHH)

October 2021

Australasian Gastro-Intestinal Trials Group (AGITG)

October 2021

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)

September 2021

Society of Hematologic Oncology (SOHO)

September 2021

Hematology Society of Australia and New Zealand (Blood)

September 2021

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2021 (Virtual)
September 2021

International Workshop on CLL (iwCLL)

September 2021

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2021 (Virtual)

Abstracts

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study) Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC) Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
September 2021

French Society of Hematology (SFH)

September 2021

World Congress on Lung Cancer (WCLC)

September 2021

Polish Society of Hematology and Transfusion Medicine (PTHiT)

August 2021

Pan Pacific Lymphoma Conference (PPLC)

July 2021

International Symposium of Yonsei Song-dang Institute for Cancer Research (N/A)

International Symposium of Yonsei Song-dang Institute for Cancer Research (N/A)

July 2021 (Seoul, South Korea)
June 2021

World Congress on Gastrointestinal Cancer (WCGI)

June 2021

International Conference on Malignant Lymphoma (ICML)

June 2021

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2021 (Virtual)
June 2021

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

June 2021 (Virtual)

Posters

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer Efficacy and safety of zanubrutinib versus rituximab-based chemotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 The effects of tislelizumab treatment on the health-related quality of life of non−small cell lung cancer patients who progressed on a prior platinum-containing regimen Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress

Abstracts

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) vs pembrolizumab (PEM) in programmed death ligand 1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): matching-adjusted indirect comparisons PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 Real-world treatment patterns, adherence, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the United States The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical hodgkin lymphoma (cHL): long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
May 2021

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

April 2021

American Association for Cancer Research (AACR)

March 2021

European Lung Cancer Congress (ELCC)

March 2021

Japanese Gastric Cancer Association (JGCA)

January 2021

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

December 2020

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

December 2020 (Virtual)
December 2020

American Society of Hematology (ASH)

American Society of Hematology (ASH)

December 2020 (Virtual)
November 2020

Society for Neuro - Oncology (SNO)

November 2020

International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)

November 2020

Society for Immunotherapy of Cancer (SITC)

Society for Immunotherapy of Cancer (SITC)

November 2020 (Virtual)
October 2020

North America Conference on Lung Cancer (NACLC)

September 2020

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2020 (Virtual)

Abstracts

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non‑small cell lung cancer (NSCLC): a phase 3 trial in progress Phase 3 trial in progress: tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma Phase 3 trial in progress: tislelizumab vs placebo in combination with concurrent chemoradiotherapy (cCRT) in patients with localized esophageal squamous cell carcinoma (ESCC) Platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with extensive-stage small cell lung cancer: A phase 3 trial in progress RATIONALE 304: tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line (1L) treatment for advanced squamous non‑small cell lung cancer (sq NSCLC) Tislelizumab + chemotherapy versus placebo + chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer: a phase 3 trial-in-progress Tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC) Tislelizumab plus standard chemotherapy and health-related quality of life In patients with advanced squamous non-small cell lung cancer Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
September 2020

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2020 (Virtual)
September 2020

Association of VA Hematology/Oncology (AVAHO)

July 2020

World Congress on Gastrointestinal Cancer (WCGI)

June 2020

American Association for Cancer Research (AACR)

June 2020

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2020 (Virtual)
May 2020

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

May 2020 (Virtual)

Abstracts

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma BGB-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC) Phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL) Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study
May 2020

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

February 2020

American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)

January 2020

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

December 2019

European Society for Medical Oncology-Immuno Oncology (ESMO-IO)

December 2019

American Society of Hematology (ASH)

American Society of Hematology (ASH)

December 2019 (Orlando, FL, United States)

Abstracts

A quantitative systems pharmacology (qsp) model to predict receptor occupancy of Bruton's tyrosine kinase (BTK) inhibitors in peripheral blood mononuclear cells, bone marrow and lymph nodes of patients with B-cell malignancies ALPINE: phase 3 trial of zanubrutinib (BGB-3111) vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) An update on safety and preliminary efficacy of highly specific Bruton tyrosine kinase (BTK) inhibitor zanubrutinib in combination with PD-1 inhibitor tislelizumab in patients with previously treated B-cell lymphoid malignancies BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from Arm C of the SEQUOIA (BGB-3111-304) trial Exposure-response relationship of the Bruton tyrosine kinase inhibitor, zanubrutinib (BGB-3111) in patients with hematologic malignancies Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma (R/R FL) Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial
November 2019

European Society for Medical Oncology-Asia (ESMO-Asia)

November 2019

Society for Neuro-Oncology (SNO)

November 2019

International Society for Pharmacoeconomics and Outcomes Research-Europe (ISPOR-EU)

September 2019

International Workshop on CLL (iwCLL)

September 2019

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2019 (Xiamen, Fugian, China)

Posters

A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresctable or metastatic solid tumors with microsatellite instablity-high or mismatch repair deficiency A phase 3 trial In progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer Dose escalation of pamiparib in Chinese patients with high-hrade non-mucinous ovarian cancer or advanced triple-negative breast cancer Pamiparib, an investigational PARP 1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (FG/GEJ) adenocarcinoma: RATIONALE 305 Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma: a phase 3 trial in progress Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B cell malignancies: follow up report of a phase 1 trial in China

Abstracts

A phase 1B study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients (pts) with advanced solid tumors A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresectable or metastatic solid tumors with microsatellite instability-high or mismatch repair deficiency A phase 3 trial in progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer Dose escalation of pamiparib in Chinese patients with high-grade non-mucinous ovarian cancer (HGOC) or advanced triple-negative breast cancer (TNBC) Pamiparib, an investigational PARP1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) Phase 3 study comparing tislelizumab in combination with cisplatin/carboplatin + gemcitabine with placebo in combination with cisplatin/carboplatin + gemcitabine as treatment for Chinese patients with advanced urothelial carcinoma: a trial in progress Phase 3 trial in progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer (SCLC) RATIONALE 306: A randomized, placebo-controlled, double-blind trial in progress of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma Safety and efficacy in patients with long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human phase 1 study The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a phase 2 study Tislelizumab in Chinese patients (pts) with esophageal cancer (EC), gastric cancer (GC), hepatocellular carcinoma (HCC), and microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) tumors Tislelizumab in Chinese patients (pts) with non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC) Tislelizumab in Chinese patients with melanoma, urothelial carcinoma (UC), and renal cell carcinoma (RCC) Tislelizumab in combination with chemotherapy as treatment for Chinese patients with esophageal squamous cell carcinoma (ESCC) Tislelizumab plus chemotherapy as first-line treatment for Chinese patients with lung cancer Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: RATIONALE 305 Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma (ESCC): A phase 3 trial in progress Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B-cell malignancies: follow-up report of a phase 1 trial in China
September 2019

World Congress on Lung Cancer (WCLC)

September 2019

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2019 (Barcelona, Spain)
June 2019

International Conference on Malignant Lymphoma (ICML)

June 2019

European Hematology Association (EHA)

May 2019

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

May 2019 (Chicago, IL, United States)

Abstracts

A phase 3 trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma A randomized, placebo-controlled, phase 3 trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC) ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Current treatment patterns and associated outcomes in Waldenström macroglobulinemia (WM) and related hematologic malignancies: a systematic literature review (SLR) Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC) Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab (obi) vs obi monotherapy in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients
May 2019

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

March 2019

American Association for Cancer Research (AACR)

February 2019

American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)

January 2019

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

December 2018

European Society for Medical Oncology-Immuno Oncology (ESMO-IO)

December 2018

American Society of Hematology (ASH)

November 2018

Society for Neuro-Oncology (SNO)

October 2018

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

October 2018 (Munich, Germany)